m6A-centered Disease Response Information
General Information of the Disease (ID: M6ADIS0160)
| Name |
Neuroendocrine neoplasms
|
||||
|---|---|---|---|---|---|
| ICD |
ICD-11: 2D4Y
|
||||
Full List of Target Gene(s) of This m6A-centered Disease Response
Histone-lysine N-methyltransferase EZH2 (EZH2)
| In total 1 item(s) under this target gene | ||||
| Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [1] | |||
| Response Summary | This data identify IGF2BP1 as an important driver of tumor progression in NEN, and indicate that disruption of the IGF2BP1-Myc-Histone-lysine N-methyltransferase EZH2 (EZH2) axis represents a promising approach for targeted therapy of neuroendocrine neoplasms. | |||
| Responsed Disease | Neuroendocrine neoplasms [ICD-11: 2D4Y] | |||
| Target Regulator | Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) | READER | ||
| Target Regulation | Up regulation | |||
| Pathway Response | Cell cycle | hsa04110 | ||
| Cell Process | Increase in G1 and sub-G1 phases | |||
| In-vitro Model | NCI-H727 | Lung carcinoid tumor | Homo sapiens | CVCL_1584 |
| COLO 320DM | Colon adenocarcinoma | Homo sapiens | CVCL_0219 | |
| In-vivo Model | RIP1-Tag2 mice were purchased from NCI Mouse Repository (Bethesda, Rockville, MD, USA) and maintained in a C57BL/6N background. | |||
Full List of Crosstalk(s) between m6A Modification and Epigenetic Regulation Related to This Disease
| In total 1 item(s) under this disease | ||
| Crosstalk ID: M6ACROT03200 | ||
| m6A Regulator | Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) | |
| m6A Target | Histone-lysine N-methyltransferase EZH2 (EZH2) | |
| Epigenetic Regulator | Histone-lysine N-methyltransferase EZH2 (EZH2) | |
| Regulated Target | Histone H3 lysine 27 trimethylation (H3K27me3) | |
| Crosstalk relationship | m6A → Histone modification | |